# EDGAR Filing Document

**Accession Number:** 0001685316
**File Stem:** 0001193125-23-000259
**Filing Date:** 2023-1
**Character Count:** 5300
**Document Hash:** d64d5e171f9ddee262ffec2334a451f9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-000259.hdr.sgml**: 20230103

**ACCESSION NUMBER**: 0001193125-23-000259

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230103

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230103

**DATE AS OF CHANGE**: 20230103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ObsEva SA
- **CENTRAL INDEX KEY:** 0001685316
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37993
- **FILM NUMBER:** 23500239

**BUSINESS ADDRESS:**
- **STREET 1:** CHEMIN DES AULX, 12
- **CITY:** PLAN-LES-OUATES
- **STATE:** V8
- **ZIP:** 1228
- **BUSINESS PHONE:** 0041-0-22-552-1558

**MAIL ADDRESS:**
- **STREET 1:** CHEMIN DES AULX, 12
- **CITY:** PLAN-LES-OUATES
- **STATE:** V8
- **ZIP:** 1228

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 3, 2023

------

## OBSEVA SA

#### (Exact name of registrant as specified in its Charter)

------

---

| | | |
|:---|:---|:---|
| **Switzerland** | **001-37993** | **Not Applicable** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **Chemin des Aulx, 12**<br> **1228 Plan-les-Ouates**<br> **Geneva, Switzerland** | **1228** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

#### + 41 22 552 38 40

#### (Registrant's telephone number, including area code)

#### Not Applicable

#### (Former name or former address, if changed since last report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common shares, par value CHF 1/13 per share | OBSV | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 7.01. Regulation FD Disclosure.
*Domestic Issuer Status* 

Effective January 1, 2023, ObsEva SA (the "Company") will begin to file periodic reports and registration statements on U.S. domestic issuer forms with the Securities and Exchange Commission, which are more detailed and extensive in certain respects, and which must be filed more promptly than the forms available to a "foreign private issuer" as defined in Rule 405 under the Securities Act of 1933, as amended. Prior to January 1, 2023, the Company qualified as a foreign private issuer.

*Disclosure Channels to Disseminate Information* 

The Company announces material information to the public about the Company, its product candidates and other matters through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company's website (www.obseva.com), the investor relations section of its website (www.obseva.com/investors), and/or social media, including its LinkedIn account (https://www.linkedin.com/company/obseva-sa/), in order to achieve broad, non-exclusionary distribution of information to the public. The Company encourages investors and others to review the information it makes public in these locations, as such information could be deemed to be material information. Please note that this list may be updated from time to time.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ObsEva SA** | **ObsEva SA** |
| Dated: January 3, 2023 | By: | /s/ Brian O'Callaghan |
|  |  | Brian O'Callaghan |
|  |  | Chief Executive Officer |

---